Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04244552
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:23.330403+00:00
Published At
2023-12-29T00:00:00+00:00
Record Updated At
2023-12-29
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Breast Cancer", "Colorectal Cancer", "Ovarian Cancer", "Non-Small Cell Lung Cancer", "Acral Lentiginous Melanoma", "Head and Neck Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Esophageal Squamous Cell Carcinoma", "Urothelial Carcinoma", "DMMR Colorectal Cancer", "MSI-H Colorectal Cancer", "Melanoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Epithelial Ovarian Cancer", "Triple Negative Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-12-29"
protocolSection.identificationModule.nctId
"NCT04244552"
protocolSection.identificationModule.officialTitle
"A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Breast Cancer (protocolSection.conditionsModule.conditions)
  • Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Non-Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Acral Lentiginous Melanoma (protocolSection.conditionsModule.conditions)
  • Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • DMMR Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • MSI-H Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Platinum-Resistant Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Resistant Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Platinum-Resistant Epithelial Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.